Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2808-03 Phase 2 study in multiple system atrophy
jRCT2041230153Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of ONO-2808 in multiple system atrophy (MSA) (4 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs), Vital signs and 4 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
ONO-2808
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on jRCT2041230153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230153.